EGFR and non-small cell lung carcinoma: Treatment modalities for BMs from EGFR-mt NSCLC patients were comprised of EGFR-TKI (76.4%), surgical resection (6.3%), SRS (53.5%), WBRT (30.0%), and immune checkpoint inhibitors (ICIs) (4.0%).